Liquid biopsy startup Freenome Inc., of South San Francisco, reeled in $160 million in a series B financing that was led by RA Capital Management and Polaris Partners. The funds are earmarked to advance Freenome's multiomics blood testing platform for early cancer detection and to grow its laboratory and software capabilities.